PRO-PSC-001
Primary Sclerosing Cholangitis (PSC)
Key Facts
About ProdIgY Biotech
ProdIgY Biotech is developing first-in-class, orally administered IgY antibody therapies that target the gut-liver axis to treat serious liver diseases, starting with alcohol-associated hepatitis (AH). Its lead candidate, PRO-AH-001, is designed to selectively neutralize the bacterial toxin cytolysin and its producer, addressing a root cause of disease progression with a non-systemic mechanism. Founded in 2018 and based in San Diego, the company is privately held and pre-revenue, with a preclinical pipeline that also includes programs for Primary Sclerosing Cholangitis (PSC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The technology is supported by peer-reviewed research, including a 2023 cover publication in Hepatology.
View full company profileTherapeutic Areas
Other Primary Sclerosing Cholangitis (PSC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ORBCEL™ for Primary Sclerosing Cholangitis | Orbsen Therapeutics | Pre-clinical/Research |
| 4P025 | 4P-Pharma | Discovery |
| Volixibat | Mirum Pharmaceuticals | Phase 2b |
| Elafibranor (GFT505) | Genfit | Phase 2 |
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2a |